Last reviewed · How we verify
Exforge®
At a glance
| Generic name | Exforge® |
|---|---|
| Sponsor | Dong-A Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- Bioequivalence Study of Amlodipine/Valsartan 10/160 mg Film Coated Tablets (PHASE1)
- Bioequivalence Study of CJ-30060 in Healthy Volunteers (PHASE1)
- Bioequivalence Study of CJ-30061 in Healthy Male Volunteers (PHASE1)
- Bioequivalence Study of CJ-30060 in Healthy Male Volunteers (PHASE1)
- Pharmacokinetic Interactions Between Amlodipine Besylate/Valsartan and Atorvastatin in Healthy Male Subjects (PHASE1)
- Study of Efficacy and Safety of CVAA489 in Hypertensive Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Exforge® CI brief — competitive landscape report
- Exforge® updates RSS · CI watch RSS
- Dong-A Pharmaceutical Co., Ltd. portfolio CI